| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 06/13/2002 | CA2430993A1 G-protein coupled receptors |
| 06/13/2002 | CA2430989A1 Method of collecting placental stem cells |
| 06/13/2002 | CA2430966A1 Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto |
| 06/13/2002 | CA2430844A1 Aryl ether substituted imidazoquinolines |
| 06/13/2002 | CA2430769A1 Novel estrogen receptor ligands and methods iii |
| 06/13/2002 | CA2430712A1 Schizophrenia-related voltage-gated ion channel gene and protein |
| 06/13/2002 | CA2430558A1 Proteins and nucleic acids encoding same |
| 06/13/2002 | CA2430466A1 Klainetin and derivatives thereof, method for their production and the use of the same |
| 06/13/2002 | CA2430379A1 Endogenous retroviruses up-regulated in prostate cancer |
| 06/13/2002 | CA2430376A1 Semicarbazides and their uses as cyclin dependent kinase inhibitors |
| 06/13/2002 | CA2430206A1 Screening method for identifying compounds that selectively induce interferon alpha |
| 06/13/2002 | CA2429728A1 Tyrosine kinase inhibitors |
| 06/13/2002 | CA2429641A1 Kinases and phosphatases |
| 06/13/2002 | CA2429258A1 Piperidine/piperazine-type inhibitors of p38 kinase |
| 06/13/2002 | CA2428390A1 Enzymes |
| 06/13/2002 | CA2428208A1 Lipid-associated molecules |
| 06/13/2002 | CA2428097A1 Immunomodulatory protein derived from the yaba monkey tumor virus |
| 06/13/2002 | CA2427430A1 Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4 |
| 06/13/2002 | CA2426158A1 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof |
| 06/13/2002 | CA2363575A1 Crystal structure |
| 06/12/2002 | EP1213291A1 Spiro [1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine for use in the treatment of psychotic and intellectual impairment disorders |
| 06/12/2002 | EP1213290A1 Dihydrobenzofuran derivatives, process for the preparation thereof and agents |
| 06/12/2002 | EP1213289A1 N-benzenesulfonyl L-proline compounds as bradykinin antagonists |
| 06/12/2002 | EP1213031A2 Combination treatment for depression, anxiety and psychosis comprising an antidepressant and/or anxiolytic and a D4 receptor antagonist |
| 06/12/2002 | EP1213026A1 Brain cell or nerve cell protecting agents comprising ginseng |
| 06/12/2002 | EP1213016A2 Chip systems for controlled emission of chemosensorically active agents |
| 06/12/2002 | EP1212941A2 Modulating ramp activity |
| 06/12/2002 | EP1212436A2 Protein phosphatase and kinase proteins |
| 06/12/2002 | EP1212433A2 Protein phosphatases and diagnosis and treatment of phosphatase-related disorders |
| 06/12/2002 | EP1212422A2 Human ctla-4 antibodies and their uses |
| 06/12/2002 | EP1212421A1 Gas1 polypeptides |
| 06/12/2002 | EP1212420A1 Conditional immortalisation of cells |
| 06/12/2002 | EP1212418A2 p193 PROTEINS AND NUCLEIC ACIDS, AND USES THEREOF |
| 06/12/2002 | EP1212416A2 Nucleic acid based modulators of gene expression |
| 06/12/2002 | EP1212407A1 Immunoglobulin superfamily polynucleotides, polypeptides, and antibodies |
| 06/12/2002 | EP1212363A2 Il-16 antagonists |
| 06/12/2002 | EP1212355A2 Pharmaceutical compositions and methods of using secreted frizzled related protein |
| 06/12/2002 | EP1212353A1 Small cyclic mimics of brain-derived neurotrophic factor (bdnf) |
| 06/12/2002 | EP1212344A1 B7-like polynucleotides, polypeptides, and antibodies |
| 06/12/2002 | EP1212335A1 Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-1- 4-(2-amin-1-yl-ethoxy)-benzyl]-1h-indol-5-ols |
| 06/12/2002 | EP1212328A1 Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| 06/12/2002 | EP1212327A2 Pyrazolopyrimidines as therapeutic agents |
| 06/12/2002 | EP1212324A1 Imidazo-triazine derivatives as ligands for gaba receptors |
| 06/12/2002 | EP1212323A2 Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
| 06/12/2002 | EP1212320A2 Phenylpiperazines as serotonin reuptake inhibitors |
| 06/12/2002 | EP1212319A2 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission |
| 06/12/2002 | EP1212317A1 Indole derivatives and their use for the treatment of osteoporosis amongst other applications |
| 06/12/2002 | EP1212309A1 Caspase inhibitor |
| 06/12/2002 | EP1212306A2 Hydroxyalkanoylaminolactams and related structures as inhibitors of abeta protein production |
| 06/12/2002 | EP1212302A1 Compounds and pharmaceutical compositions as cathepsin s inhibitors |
| 06/12/2002 | EP1212301A1 Arylalkyloxyalkylamines and arylalkylthioalkylamines, pharmaceutical compositions containing them and their use as inhibitors of nicotinic cholinergic receptors |
| 06/12/2002 | EP1212299A1 Substituted piperidine compounds useful as modulators of chemokine receptor activity |
| 06/12/2002 | EP1212298A1 Isolation of natural l-beta-3-indolylalanine and enrichment of natural aliphatic amino acid mixtures with natural l-beta-3-indolylalanine |
| 06/12/2002 | EP1212297A1 4-amino-1-aryl-1,5-dihydro-pyrrole-2-one with anti-convulsive and anxiolytic properties and a method for producing the same |
| 06/12/2002 | EP1212296A1 Phosphate mimics and methods of treatment using phosphatase inhibitors |
| 06/12/2002 | EP1212295A1 SUBSTITUTED $g(a)-HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF |
| 06/12/2002 | EP1212120A2 Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents, for producing long lasting antineoplastic agents |
| 06/12/2002 | EP1212119A1 Use of cyamemazine for cold turkey benzodiazepine treatment |
| 06/12/2002 | EP1212088A1 Method for treatment of symptoms of central nervous system disorders |
| 06/12/2002 | EP1212087A1 Methods and compositions utilizing rad51 |
| 06/12/2002 | EP1212086A1 Immunological tolerance-induction agent |
| 06/12/2002 | EP1212061A1 Injectable buprenorphine microparticle compositions and their use in reducing consumption of heroin and alcohol |
| 06/12/2002 | EP1212060A1 Use of nicotine or derivatives thereof in a medicine for treating neurological diseases, in particular parkinson disease |
| 06/12/2002 | EP1212056A1 Methods and compositions for bisubstrate inhibitors of acetyltransferases |
| 06/12/2002 | EP1212055A1 Neurotherapeutic composition and method |
| 06/12/2002 | EP1212054A2 Azetidine compounds in cns and eye diseases |
| 06/12/2002 | EP1212052A2 Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate |
| 06/12/2002 | EP1212048A1 Use of sigma receptor agonists for the treatment of depression |
| 06/12/2002 | EP1212000A1 Method of controlling body temperature while reducing shivering |
| 06/12/2002 | EP1032571B1 Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance p antagonists |
| 06/12/2002 | EP1028947B1 H3 receptor ligands of the phenyl-alkyl-imidazoles type |
| 06/12/2002 | EP1023287B1 3-oxo-2(h)-1,2,4-triazine derivatives as ligands of 5ht1a receptors |
| 06/12/2002 | EP1023263B1 Novel vitamin d analogues |
| 06/12/2002 | EP0984778B1 Neuropeptide-y ligands |
| 06/12/2002 | EP0888327B1 Benzopyran derivatives having leukotriene-antagonistic action |
| 06/12/2002 | EP0885221B1 Azabicyclic esters of carbamic acids useful in therapy |
| 06/12/2002 | EP0885210B1 Tricylic compounds having binding affinity for melatonin receptors, their production and use |
| 06/12/2002 | EP0885204B1 Novel aryl glycinamide derivatives, method of producing said derivatives and pharmaceutical compositions containing these compounds |
| 06/12/2002 | EP0873320B1 Piperazine derivatives as tachykinin antagonists |
| 06/12/2002 | EP0873312B1 Alpha-substituted arylsulphonamido hydroxamic acids as tnf-alpha and matrix metalloproteinase inhibitors |
| 06/12/2002 | EP0825857B1 Use of gabapentin and its derivatives in the treatment of mania and bipolar disorder |
| 06/12/2002 | EP0808314B1 Forms of paroxetin hydrochloride |
| 06/12/2002 | EP0802800B1 Biocompatible immunoisolatory capsules containing genetically altered cells for the delivery of biologically active molecules |
| 06/12/2002 | EP0772603B1 Substituted pyrimidine compounds and their use |
| 06/12/2002 | EP0751939B1 Naphthylamides as central nervous system agents |
| 06/12/2002 | EP0737200B1 Biologically active silicon compounds and their therapeutic and cosmetic applications |
| 06/12/2002 | EP0734259B1 Use of piperidine compounds in the treatment of schizophrenia |
| 06/12/2002 | EP0652867B1 Novel pyridyl- and pyrimidylpiperazine derivatives |
| 06/12/2002 | EP0625982B1 4-oxo- and 4h-imidazo(5,1-c)(1,4)benzoxazines useful as benzodiazepine receptor-binding agents |
| 06/12/2002 | CN1353816A Method for identifying individual at risk for irreversible neurodamages, comprising steps of determining quantatively concentration of pepsinogen I(PGI) and vitamin B12 |
| 06/12/2002 | CN1353754A Variants of TRAF2 which act as an inhibitor of TNF-alpha (TNF alpha) signaling pathway |
| 06/12/2002 | CN1353714A Triazolopyrimidinol compounds and salts thereof |
| 06/12/2002 | CN1353713A Purine inhibitors of cyclin dependent kinase 2 and IK B-alpha |
| 06/12/2002 | CN1353712A Polymorphs of crystalline (2-benzhydryl-2-azabicyclo [2.2.2] OCT-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate as NK-1 receptor antagonists |
| 06/12/2002 | CN1353699A Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents |
| 06/12/2002 | CN1353698A Novel morpholine derivatives, method for production thereof and pharmaceutical preparations containing said derivatives |
| 06/12/2002 | CN1353697A 4-phenyl-pyrimidine derivatives |
| 06/12/2002 | CN1353696A 5-phenyl-pyrimidine derivatives |
| 06/12/2002 | CN1353695A Heterocyclically substituted benzimidazoles, production and application thereof |
| 06/12/2002 | CN1353694A Alpha-substituted carboxylic acid derivatives |